AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30900436 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 30
Study 29520385 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI) after white light cystoscopy (WLC)
Number of subjects: 198
Study 29520385 — intervention group
Group type: COMPARATOR
Intervention: White light cystoscopy (WLC) only
Number of subjects: 198
Study 29520385 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 198
Study 27027916 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-SMILE corneas
Number of subjects: 80
Study 27027916 — intervention group
Group type: COMPARATOR
Intervention: Normal eyes
Number of subjects: 80
Study 24410738 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text-message intervention (structured programme of clinic appointment, medication pick-up reminders, medication adherence support, and hypertension-related education)
Number of subjects: 0
Study 24410738 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text-message intervention (informational or interactive messages)
Number of subjects: 0
Study 24410738 — intervention group
Group type: COMPARATOR
Intervention: Usual care (supplemented by infrequent non-hypertension related SMS text-messages)
Number of subjects: 0
Study 22931079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cherokee Talking Circle (CTC) culturally‐based intervention
Number of subjects: 179
Study 22931079 — intervention group
Group type: COMPARATOR
Intervention: Be A Winner Standard Education (SE) condition
Number of subjects: 179
Study 19668123 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1051
Study 19668123 — intervention group
Group type: COMPARATOR
Intervention: SNRI
Number of subjects: 1051
Study 19668123 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (severe depression subset)
Number of subjects: 1051
Study 17515293 — intervention group
Group type: EXPERIMENTAL
Intervention: Demoksil 1 g tablet (test preparation)
Number of subjects: 0
Study 17515293 — intervention group
Group type: COMPARATOR
Intervention: 1 g tablet of the originator product (reference preparation)
Number of subjects: 0
Study 17515293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference preparations
Number of subjects: 0
Study 15637979 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliClean System from Sonicare and Crest
Number of subjects: 54
Study 15637979 — intervention group
Group type: COMPARATOR
Intervention: Sonicare Elite with conventional toothpaste
Number of subjects: 54
Study 11441777 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practice in psychiatry
Number of subjects: 0
Study 11441777 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practice guidelines
Number of subjects: 0
Study 11441777 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary research
Number of subjects: 0
Study 11441777 — intervention group
Group type: EXPERIMENTAL
Intervention: Large, simple randomized trials
Number of subjects: 0
Study 11441777 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to evidence-based medicine
Number of subjects: 0
Study 11441777 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration among stakeholders
Number of subjects: 0
Study 9142380 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEP therapy (5‐fluorouracil 370 mg/m2, leucovorin 30 mg/person, cisplatinum 70 mg/m2, etoposide 70 mg/m2)
Number of subjects: 30
Study 9142380 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEP therapy followed by surgery
Number of subjects: 30
Study 9142380 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative surgery after FLEP therapy
Number of subjects: 30
Study 7535443 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐/G‐CSF treatment prior to harvest
Number of subjects: 0
Study 7535443 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control)
Number of subjects: 0
Study 3495732 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole given daily
Number of subjects: 166
Study 3495732 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole given three consecutive days a week
Number of subjects: 166
Study 31774015 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training for at least 30 months
Number of subjects: 10
Study 31774015 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining after at least 20 months of aerobic training
Number of subjects: 10
Study 31774015 — intervention group
Group type: COMPARATOR
Intervention: Baseline and follow-up measurements
Number of subjects: 10
Study 29329484 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg daily
Number of subjects: 1360
Study 29329484 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 35 mg weekly
Number of subjects: 1360
Study 27545024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmentation to dust (group I, n=50)
Number of subjects: 100
Study 27545024 — intervention group
Group type: COMPARATOR
Intervention: Fragmentation into extractable fragments (group II, n=50)
Number of subjects: 100
Study 24525954 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire Flow Restoration with the Intention for Thrombectomy (SWIFT) intervention
Number of subjects: 139
Study 24525954 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline ASPECTS (8-10; n=109)
Number of subjects: 139
Study 24525954 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure
Number of subjects: 139
Study 24525954 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline blood glucose
Number of subjects: 139
Study 24525954 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure to achieve Thrombolysis in Cerebral Infarction score of 2b/3 reperfusion
Number of subjects: 139
Study 22107759 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 73
Study 22107759 — intervention group
Group type: COMPARATOR
Intervention: Control (deflated cuff for 30 min)
Number of subjects: 73
Study 19887114 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese traditional diet (JTD)
Number of subjects: 25
Study 19887114 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 25
Study 18413220 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol-370 (low osmolar, monomeric)
Number of subjects: 122
Study 18413220 — intervention group
Group type: COMPARATOR
Intervention: iodixanol-320 (iso-osmolar, dimeric)
Number of subjects: 122
Study 15707470 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 8 mg
Number of subjects: 540
Study 15707470 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (AML) 5 mg
Number of subjects: 540
Study 12505966 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastroplasty (Group 1)
Number of subjects: 60
Study 12505966 — intervention group
Group type: COMPARATOR
Intervention: Open laparotomy gastroplasty (Group 2)
Number of subjects: 60
Study 10639526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) inhalation at 25 ppm with supplemental oxygen at 2 l/min via nasal cannula for 24 hours
Number of subjects: 11
Study 10639526 — intervention group
Group type: COMPARATOR
Intervention: Room air with supplemental oxygen at 2 l/min via nasal cannula for 24 hours (control)
Number of subjects: 11
Study 8672620 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 109
Study 8672620 — intervention group
Group type: COMPARATOR
Intervention: Other antibiotics
Number of subjects: 109
Study 1332988 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of metronidazole 25% gel
Number of subjects: 24
Study 1332988 — intervention group
Group type: COMPARATOR
Intervention: Subgingival scaling
Number of subjects: 24
Study 2862371 — intervention group
Group type: COMPARATOR
Intervention: Exclusion diet
Number of subjects: 20
Study 2862371 — intervention group
Group type: COMPARATOR
Intervention: Unrefined carbohydrate fibre rich diet
Number of subjects: 20
Study 2862371 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion diet (in uncontrolled study)
Number of subjects: 20
Study 30099496 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI with SrCl2 AOA
Number of subjects: 343
Study 30099496 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI with calcimycin AOA
Number of subjects: 343
Study 30099496 — intervention group
Group type: COMPARATOR
Intervention: ICSI alone
Number of subjects: 343
Study 30099496 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI with SrCl2 AOA (for couples with previous ICSI cycles of low fertilization)
Number of subjects: 343
Study 30099496 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI with calcimycin AOA (for couples affected by male-factor infertility)
Number of subjects: 343
Study 27187898 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block (SGB)
Number of subjects: 100
Study 27187898 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 100
Study 27187898 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block (SGB) - second treatment
Number of subjects: 100
Study 26458126 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD A-D classification
Number of subjects: 0
Study 26458126 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0
Study 26458126 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 0
Study 26458126 — intervention group
Group type: COMPARATOR
Intervention: GOLD I-IV classification
Number of subjects: 0
Study 23623245 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 8
Study 23623245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM)
Number of subjects: 8
Study 23623245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 8
Study 23623245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 21146678 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel
Number of subjects: 400
Study 21146678 — intervention group
Group type: COMPARATOR
Intervention: 300 mg clopidogrel
Number of subjects: 400
Study 18937864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with house dust mite allergen
Number of subjects: 251
Study 18937864 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 251
Study 16645137 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 15943
Study 14740954 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate live-attenuated dengue virus vaccine
Number of subjects: 0
Study 11271080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion starting with an initial dosage of 5 microg x kg x min, increased to a maximum of 10 microg x kg x min.
Number of subjects: 30
Study 11271080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 30
Study 11271080 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between VO2,IC and VO2,Fick
Number of subjects: 30
Study 8831306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mean arterial pressure (50-60 mm Hg) during cardiopulmonary bypass
Number of subjects: 248
Study 8831306 — intervention group
Group type: EXPERIMENTAL
Intervention: High mean arterial pressure (80-100 mm Hg) during cardiopulmonary bypass
Number of subjects: 248
Study 8831306 — intervention group
Group type: EXPERIMENTAL
Intervention: Atheromatous disease of the descending aorta graded from I to V
Number of subjects: 248
Study 1482778 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational material on diabetic eye disease and examination findings conveyed to participants and their primary physician
Number of subjects: 619
Study 1482778 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group (n = 241)
Number of subjects: 619
Study 3007250 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg qid
Number of subjects: 14
Study 3007250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30420291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ω‐3 Long‐Chain PolyUnsaturated Fatty Acids (Ω‐3LCPUFA) 2.9 g/d
Number of subjects: 28
Study 30420291 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (placebo)
Number of subjects: 28
Study 29394355 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotarix
Number of subjects: 100
Study 27017514 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 1132
Study 27017514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1132
Study 23913440 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemi-CC7 transfer for hand function (Group 1, n = 20)
Number of subjects: 40
Study 23913440 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-CC7 transfer (Group 2, n = 20)
Number of subjects: 40
Study 23913440 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous neurotization on both suprascapular and axillary nerves
Number of subjects: 40
Study 22773704 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril and delapril (specific dosages not mentioned)
Number of subjects: 600
Study 22773704 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent hyperfiltration
Number of subjects: 600
Study 22773704 — intervention group
Group type: COMPARATOR
Intervention: Ameliorated hyperfiltration
Number of subjects: 600
Study 22773704 — intervention group
Group type: EXPERIMENTAL
Intervention: Amelioration of hyperfiltration
Number of subjects: 600
Study 20433027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate 8 mg (2 mL) intravenous
Number of subjects: 62
Study 20433027 — intervention group
Group type: COMPARATOR
Intervention: Saline solution 2 mL intravenous (control)
Number of subjects: 62
Study 17019380 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical acupuncture
Number of subjects: 103
Study 17019380 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 103
Study 16224674 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak pulsing magnetic fields (daily exposure for 16 minutes over 6 weeks, frequencies of 10, 20, 30, and 200-300 Hz, flux densities from 3.4 to 13.6 microT)
Number of subjects: 71
Study 16224674 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 71
Study 16224674 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak pulsing magnetic fields (after 4 weeks without therapy)
Number of subjects: 71
Study 11908555 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 2302 (0.5 mg/kg)
Number of subjects: 43
Study 11908555 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 2302 (1 mg/kg)
Number of subjects: 43
Study 11908555 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 2302 (2 mg/kg)
Number of subjects: 43
Study 11908555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 11908555 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 2302 (all doses)
Number of subjects: 43
Study 10076618 — intervention group
Group type: EXPERIMENTAL
Intervention: D4 lymphadenectomy (group A, n = 35)
Number of subjects: 70
Study 10076618 — intervention group
Group type: COMPARATOR
Intervention: D3 lymphadenectomy (group B, n = 35)
Number of subjects: 70
Study 10076618 — intervention group
Group type: EXPERIMENTAL
Intervention: D4 lymphadenectomy (group A)
Number of subjects: 70
Study 10076618 — intervention group
Group type: COMPARATOR
Intervention: D3 lymphadenectomy (group B)
Number of subjects: 70
Study 7552604 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 10%
Number of subjects: 29
Study 7552604 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 10%/amino acids
Number of subjects: 29
Study 7552604 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 10%/amino acids/lipid
Number of subjects: 29
Study 7552604 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 29
Study 1522840 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (7 mg)
Number of subjects: 650
Study 1522840 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine (1 mg)
Number of subjects: 650
Study 6822657 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine for 14 days
Number of subjects: 5
Study 6822657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6822657 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 5
Study 30870416 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole cell-only oral cholera vaccine (WC-only OCV)
Number of subjects: 50770
Study 30870416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50770
Study 28838276 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Number of subjects: 710
Study 27391795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 16
Study 24368553 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (n = 8)
Number of subjects: 16
Study 24368553 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 16
Study 22762978 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group C)
Number of subjects: 160
Study 22762978 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 20 mg (Group P(20))
Number of subjects: 160
Study 22762978 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg (Group P(40))
Number of subjects: 160
Study 22762978 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg (Group L)
Number of subjects: 160
Study 20819323 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 242
Study 20819323 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 242
Study 17620811 — intervention group
Group type: EXPERIMENTAL
Intervention: Imageless navigation system
Number of subjects: 200
Study 17620811 — intervention group
Group type: COMPARATOR
Intervention: Conventional implantation instruments
Number of subjects: 200
Study 17620811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 16391484 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study 16391484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11965514 — intervention group
Group type: EXPERIMENTAL
Intervention: Olibra fat (0, 2, 4, 6 g) in yoghurt
Number of subjects: 50
Study 11965514 — intervention group
Group type: COMPARATOR
Intervention: Control yoghurt (0 g Olibra)
Number of subjects: 50
Study 11965514 — intervention group
Group type: EXPERIMENTAL
Intervention: Olibra fat (0, 2, 4, 6 g)
Number of subjects: 50
Study 10495984 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/day
Number of subjects: 0
Study 10495984 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 12.5-17.5 mg/day
Number of subjects: 0
Study 10495984 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 10495984 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 10495984 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 7560247 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 193
Study 7560247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 1689791 — intervention group
Group type: EXPERIMENTAL
Intervention: iloprost
Number of subjects: 133
Study 1689791 — intervention group
Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 133
Study 7267697 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam with 120 ml water, preceded by 120 ml of a 50:50 vodka:water mixture
Number of subjects: 6
Study 7267697 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam with 120 ml of the vodka mixture, preceded by 120 ml of water
Number of subjects: 6
Study 7267697 — intervention group
Group type: COMPARATOR
Intervention: diazepam with 120 ml of water, preceded 30 min before with 120 ml of water (control)
Number of subjects: 6
Study 30370658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 30370658 — intervention group
Group type: COMPARATOR
Intervention: Placebo cessation
Number of subjects: 360
Study 30370658 — intervention group
Group type: COMPARATOR
Intervention: Placebo noncessation
Number of subjects: 360
Study 28750582 — intervention group
Group type: EXPERIMENTAL
Intervention: MIN-101 32 mg/day
Number of subjects: 244
Study 28750582 — intervention group
Group type: EXPERIMENTAL
Intervention: MIN-101 64 mg/day
Number of subjects: 244
Study 28750582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 28750582 — intervention group
Group type: EXPERIMENTAL
Intervention: MIN-101 32 mg/day and 64 mg/day
Number of subjects: 244
Study 28750582 — intervention group
Group type: COMPARATOR
Intervention: MIN-101 and Placebo
Number of subjects: 244
Study 27264884 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body passive hyperthermia treatment (1h in 39.4±0.4°C water)
Number of subjects: 18
Study 27264884 — intervention group
Group type: COMPARATOR
Intervention: Control resting condition
Number of subjects: 18
Study 24433977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine supplementation
Number of subjects: 0
Study 24433977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22038146 — intervention group
Group type: EXPERIMENTAL
Intervention: Incline plyometrics training (15° incline), 4 weeks, 4 times per week, 8 sets of 10 jumps per session.
Number of subjects: 20
Study 22038146 — intervention group
Group type: EXPERIMENTAL
Intervention: Incline plyometrics training (15° incline)
Number of subjects: 20
Study 22038146 — intervention group
Group type: COMPARATOR
Intervention: Plane plyometrics training (flat surface)
Number of subjects: 20
Study 22038146 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Incline and Plane plyometrics)
Number of subjects: 20
Study 19707579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar graph of duration of symptoms
Number of subjects: 1760
Study 19707579 — intervention group
Group type: COMPARATOR
Intervention: Face icons (happy/sad)
Number of subjects: 1760
Study 19707579 — intervention group
Group type: COMPARATOR
Intervention: Bar graph showing proportion of people with symptoms on day three with and without treatment
Number of subjects: 1760